Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use LAZCLUZE safely and effectively. See full prescribing information for LAZCLUZE. LAZCLUZE ®(lazertinib) tablets, for oral use Initial U.S. Approval: 2024
Medication labelWhy this: Advisory · dailymed-prescription
LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test [see Dosage and Administration (2.1)] .
- generic_name
- lazertinib
- product_names
- lazertinib
- ndc
- 57894-240, 57894-080, 57894-240-30, 57894-240-99, 57894-080-60, 57894-080-90
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en